TERN
Terns Pharmaceuticals, Inc.
$52.95
+0.00 (+0.00%)
At close · May 7
Market Cap
$6.12B
Shares
115,521,157
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$52.95
Open$52.95
Day$52.95–52.95
52W$2.66–53.19
Avg vol 30d6.2M
Short int5.5M · 4.8% float · 1.5d
Short vol35%
Last earningsJan 9, 2026
DataFeb 2021–May 2026
Filing10-K · Mar 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Mar 30, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+86%
above
Price vs 50-day avg
+6%
above
RSI (14)
74
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+161%
trailing
YTD return
+31%
this year
Relative strength
+154%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $50 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+30% holders QoQ · +134 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.79% of float · ▼ -31.3% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
324 holders — near 3-yr high, broad support
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+8%
Y/Y
Free cash flow
$-82.2M
Balance sheet
$524.7M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
0.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+86%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
74
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $50 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+30% holders QoQ · +134 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.79% of float · ▼ -31.3% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
324 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $53 · 100%
52-wk high $53
vs 200-day avg +86%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TERN
this stock
Terns Pharmaceuticals, Inc.
|
$6.12B | +31.1% | — | — | 4.8% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.89B | +5.9% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.76B | +4.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TERN | +0.1% | +0.7% | +160.8% | +0.1% | +31.1% |
| SPY | +1.8% | +7.6% | +7.1% | +1.8% | +7.3% |
| vs SPY | -1.8% | -6.9% | +153.8% | -1.8% | +23.8% |